Detail akcie T2 Biosystems Rg online

Business Summary: T2 Biosystems, Inc. is an in vitro diagnostics company focused on the detection of sepsis-causing pathogens and antibiotic resistance genes. Its technology enables detection of pathogens, biomarkers and other abnormalities in a variety of unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum and urine, and can detect cellular targets at limits of detection as low as one colony forming unit per milliliter (CFU/mL). Its focus includes three areas: sepsis, bioterrorism, and Lyme disease. The Company's products include the T2Dx Instrument, the T2Bacteria Panel, the T2Candida Panel, the T2Resistance Panel, and the T2Biothreat Panel, and are powered by the T2 Magnetic Resonance (T2MR) technology. It also has an active pipeline of products, including the United States T2Resistance Panel, the Candida auris test, and the T2Lyme Panel. T2Dx Instrument is a fully automated instrument that is capable of running a range of diagnostic tests from patient samples.
Financial Summary: BRIEF: For the nine months ended 30 September 2024, T2 Biosystems Inc revenues increased 9% to $6M. Net loss decreased 18% to $32.6M. Revenues reflect Consumables segment increase of 28% to $4.4M, Service segment increase of 2% to $390K, international segment increase of 17% to $2.7M, domestic segment increase of 4% to $3.3M. Lower net loss reflects Interest expense to related party decrease of 52% to $2M (expense).